Magle Chemoswed Holding Ab (MAGLE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has a cash flow conversion efficiency ratio of -0.092x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-48.89 Million ≈ $-5.26 Million USD) by net assets (Skr531.75 Million ≈ $57.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Magle Chemoswed Holding Ab - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Magle Chemoswed Holding Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Magle Chemoswed Holding Ab for a breakdown of total debt and financial obligations.
Magle Chemoswed Holding Ab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Magle Chemoswed Holding Ab ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Merchant House International Ltd
AU:MHI
|
-0.197x |
|
Enjoy S.A
SN:ENJOY
|
-0.157x |
|
T.M.C. Industrial Public Company Limited
BK:TMC
|
0.011x |
|
Buxton Resources Ltd
AU:BUX
|
-0.317x |
|
Indo Straits Tbk
JK:PTIS
|
0.048x |
|
FATFISH GROUP LTD.
F:1JU
|
N/A |
|
CVS Group Plc
LSE:CVSG
|
0.145x |
|
SRJ Technologies Group Plc
AU:SRJ
|
-0.052x |
Annual Cash Flow Conversion Efficiency for Magle Chemoswed Holding Ab (2017–2024)
The table below shows the annual cash flow conversion efficiency of Magle Chemoswed Holding Ab from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see MAGLE company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr560.60 Million ≈ $60.33 Million |
Skr-11.70 Million ≈ $-1.26 Million |
-0.021x | -121.54% |
| 2023-12-31 | Skr158.22 Million ≈ $17.03 Million |
Skr15.33 Million ≈ $1.65 Million |
0.097x | +14.08% |
| 2022-12-31 | Skr146.77 Million ≈ $15.79 Million |
Skr12.47 Million ≈ $1.34 Million |
0.085x | -54.73% |
| 2021-12-31 | Skr138.79 Million ≈ $14.94 Million |
Skr26.04 Million ≈ $2.80 Million |
0.188x | +492.89% |
| 2020-12-31 | Skr116.12 Million ≈ $12.50 Million |
Skr-5.54 Million ≈ $-596.73K |
-0.048x | +23.40% |
| 2019-12-31 | Skr113.66 Million ≈ $12.23 Million |
Skr-7.08 Million ≈ $-762.46K |
-0.062x | -128.56% |
| 2018-12-31 | Skr50.67 Million ≈ $5.45 Million |
Skr11.06 Million ≈ $1.19 Million |
0.218x | -65.21% |
| 2017-12-31 | Skr42.98 Million ≈ $4.63 Million |
Skr26.96 Million ≈ $2.90 Million |
0.627x | -- |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more